Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer's disease-related animal models despite reported blood-brain barrier disruption

Drug Metabolism and Disposition

Volumn 38, Issue 8, 2010, Pages 1355-1361

  Cheng, Ziqiang ^a   Zhang, Jinqiang ^a   Liu, Houfu ^a   Li, Yi ^a   Zhao, Yonggang ^a   Yang, Eric ^a  

^a GLAXOSMITHKLINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ATENOLOL; CENTRAL NERVOUS SYSTEM AGENTS; FLUORESCEIN SODIUM; GSK A; GSK B; GSK C; LOPERAMIDE; NAPROXEN; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; DRUG BRAIN LEVEL; DRUG DETERMINATION; DRUG PENETRATION; MALE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MULTIPLE SCLEROSIS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 77954940188     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.033324     Document Type: Article

References (36)

1. Abbott NJ (2005) Dynamics of CNS barriers: evolution, differentiation, and modulation. Cell Mol Neurobiol 25:5-23.
2. Abbott NJ, Dolman DE, and Patabendige AK (2008) Assays to predict drug permeation across the blood-brain barrier, and distribution to brain. Curr Drug Metab 9:901-910.
3. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, and Begley DJ (2010) Structure and function of the blood-brain barrier. Neurobiol Dis 37:13-25.
4. Bowman GL, Kaye JA, Moore M, Waichunas D, Carlson NE, and Quinn JF (2007) Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. Neurology 68:1809-1814.
5. Clark DE (2003) In silico prediction of blood-brain barrier permeation. Drug Discov Today 8:927-933.
6. Clodfelder-Miller BJ, Zmijewska AA, Johnson GV, and Jope RS (2006) Tau is hyperphosphorylated at multiple sites in mouse brain in vivo after streptozotocin-induced insulin deficiency. Diabetes 55:3320-3325.
7. Couraud PO (1998) Infiltration of inflammatory cells through brain endothelium. Pathol Biol 46:176-180. (Pubitemid 28160662)
8. Dauchy S, Dutheil F, Weaver RJ, Chassoux F, Daumas-Duport C, Couraud PO, Scherrmann JM, De Waziers I, and Declèves X (2008) ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier. J Neurochem. 107:1518-1528.
9. Davies MI (1999) A review of microdialysis sampling for pharmacokinetic applications. Anal Chim Acta 379:227-249.
10. Kooij G, Mizee M, van Horssen J, de Lange ECM, Reijerkerk A, van der Pol SMA, and de Vries E (2009) Pathophysiology of blood-brain barrier in multiple sclerosis. Proceedings of the 8th Cerebral Vascular Biology International Conference; 2009 Jun 28-Jul 2; Sendai, Japan. International Brain Barriers Society, Duluth, MN.
11. Di L, Kerns EH, and Carter GT (2008) Strategies to assess blood-brain barrier penetration. Expert Opin Drug Discov 3:677-687.
12. Fabis MJ, Phares TW, Kean RB, Koprowski H, and Hooper DC (2008) Blood-brain barrier changes and cell invasion differ between therapeutic immune clearance of neurotrophic virus and CNS autoimmunity. Proc Natl Acad Sci USA 105:15511-15516.
13. Floris S, Blezer EL, Schreibelt G, Döpp E, van der Pol SM, Schadee-Eestermans IL, Nicolay K, Dijkstra CD, and de Vries HE (2004) Blood-brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: a quantitative MRI study. Brain 127:616-627.
14. Förster C, Kahles T, Kietz S, and Drenckhahn D (2007) Dexamethasone induces the expression of metalloproteinase inhibitor TIMP-1 in the murine cerebral vascular endothelial cell line cEND. J Physiol 580:937-949.
15. Gleeson MP (2008) Generation of a set of simple, interpretable ADMET rules of thumb. J Med Chem 51:817-834.
16. Hall A, Elliott RL, Giblin GM, Hussain I, Musgrave J, Naylor A, Sasse R, and Smith B (2010) Piperidine-derived γ-secretase modulators. Bioorg Med Chem Lett. 20:1306-1311.
17. Howlett DR, Bowler K, Soden PE, Riddell D, Davis JB, Richardson JC, Burbidge SA, Gonzalez MI, Irving EA, Lawman A, et al. (2008) Aβ eposition and related pathology in an APP x PS1 transgenic mouse model of Alzheimer's disease. Histol Histopathol 23:67-76.
18. Kalvass JC and Maurer TS (2002) Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 23:327-338.
19. Koh CS, Gausas J, and Paterson PY (1993) Neurovascular permeability and fibrin deposition in the central neuraxis of Lewis rats with cell-transferred experimental allergic encephalomyelitis in relationship to clinical and histopathological features of the disease. J Neuroimmunol 47:141-145.
20. Körner H and Sedgwick JD (1996) Tumour necrosis factor and lymphotoxin: molecular aspects and role in tissue-specific autoimmunity. Immunol Cell Biol 74:465-472. (Pubitemid 26342132)
21. Kusuhara H and Sugiyama Y (2001) Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 1). Drug Discov Today 6:150-156. (Pubitemid 32098289)
22. Liu X and Chen C (2005) Strategies to optimize brain penetration in drug discovery. Curr Opin Drug Discov Devel 8:505-512.
23. Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JP, et al. (2006) Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration. Drug Metab Dispos 34:1443-1447.
24. Liu X, Van Natta K, Yeo H, Vilenski O, Weller PE, Worboys PD, and Monshouwer M (2009) Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid. Drug Metab Dispos 37:787-793.
25. Lorenzi M, Healy DP, Hawkins R, Printz JM, and Printz MP (1986) Studies on the permeability of the blood-brain barrier in experimental diabetes. Diabetologia 29:58-62.
26. Miller SD and Karpus WJ (2007) Experimental autoimmune encephalomyelitis in the mouse. Curr Protoc Immunol Chapter 15:Unit 15.1.
27. Muller DM, Pender MP, and Greer JM (2005) Blood-brain barrier disruption and lesion localisation in experimental autoimmune encephalomyelitis with predominant cerebellar and brainstem involvement. J Neuroimmunol 160:162-169.
28. Nakagawa S, Deli MA, Kawaguchi H, Shimizudani T, Shimono T, Kittel A, Tanaka K, and Niwa M (2009) A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochem Int 54:253-263.
29. Pardridge WM (2005) The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2:3-14.
30. Rausch M, Hiestand P, Baumann D, Cannet C, and Rudin M (2003) MRI-based monitoring of inflammation and tissue damage in acute and chronic relapsing EAE. Magn Reson Med 50:309-314.
31. Roberts DJ and Goralski KB (2008) A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain. Expert Opin Drug Metab Toxicol 4:1245-1264.
32. Stone LA, Smith ME, Albert PS, Bash CN, Maloni H, Frank JA, and McFarland HF (1995) Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsingremitting multiple sclerosis: relationship to course, gender, and age. Neurology 45:1122-1126.
33. Summerfield SG, Stevens AJ, Cutler L, del Carmen Osuna M, Hammond B, Tang SP, Hersey A, Spalding DJ, and Jeffrey P (2006) Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain. J Pharmacol Exp Ther 316:1282-1290.
34. Tonra JR (2002) Cerebellar susceptibility to experimental autoimmune encephalomyelitis in SJL/J mice: potential interaction of immunology with vascular anatomy. Cerebellum 1:57-68.
35. Tonra JR, Reiseter BS, Kolbeck R, Nagashima K, Robertson R, Keyt B, and Lindsay RM (2001) Comparison of the timing of acute blood-brain barrier breakdown to rabbit immunoglobulin G in the cerebellum and spinal cord of mice with experimental autoimmune encephalomyelitis. J Comp Neurol 430:131-144.
36. Zlokovic BV (2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57:178-201.